Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM) -- Ignore unavailable to you. Want to Upgrade?

To: cknox who wrote (58)	5/13/1998 8:42:00 PM
From: burner	Respond to of 134

I wouldn't think there is any other news but more a matter of increased awareness of the Immpheron research. The sector is looking for a company to catch the magic as evidenced by the cancer research company that went from 11 to 85 (dollars) last week. One can only hope the word is good and it is getting out. the stock is definitely trading with strength but after the extended time it sat near 5 cents and under I would half expect a pullback at these new levels. this one is worth keeping an ey on. I believe you might even see a write-up and analysis soon. Dan

To: cknox who wrote (58)	5/15/1998 1:50:00 AM
From: burner	Read Replies (1) \| Respond to of 134

cknox, IMM is starting to attract more than a little attention. Lou Paquette has just included an update on it in his May issue of "Emerging Growth Stocks" newsletter which is available at the Stockhouse website stockhouse.com or at info-mine.com to paraphrase him: 7 HIV infected macaques have been injected with the monoclonal antibody and preliminary responses from blood and tissue samples are good! Lou has been following IMM since the days before it was even trading and to have him following the stock this closely is a good sign. He has picked Hi-tech winners before and with his subscription base that also includes a hard copy edition of the newsletter I am starting to feel much better about owning this underfollowed stock. If he writes a full-blown report on the research this thing will really get noticed by the investing public. I'm not sure where this one is going to go but sure hope it gets the same type of respone that we have seen with PYT or OOL or IIA. Ya never know!! Regards, Dan Byrne